AU2002252731A1 - Compositions and methods of double-targeting virus infections and cancer cells - Google Patents
Compositions and methods of double-targeting virus infections and cancer cellsInfo
- Publication number
- AU2002252731A1 AU2002252731A1 AU2002252731A AU2002252731A AU2002252731A1 AU 2002252731 A1 AU2002252731 A1 AU 2002252731A1 AU 2002252731 A AU2002252731 A AU 2002252731A AU 2002252731 A AU2002252731 A AU 2002252731A AU 2002252731 A1 AU2002252731 A1 AU 2002252731A1
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- double
- methods
- cancer cells
- virus infections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/844,201 | 2001-04-27 | ||
US09/844,201 US7026469B2 (en) | 2000-10-19 | 2001-04-27 | Compositions and methods of double-targeting virus infections and cancer cells |
PCT/US2002/013338 WO2002087465A2 (en) | 2001-04-27 | 2002-04-26 | Compositions and methods of double-targeting virus infections and cancer cells |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002252731A1 true AU2002252731A1 (en) | 2002-11-11 |
Family
ID=25292094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002252731A Abandoned AU2002252731A1 (en) | 2001-04-27 | 2002-04-26 | Compositions and methods of double-targeting virus infections and cancer cells |
Country Status (6)
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1460082A1 (en) * | 2003-03-19 | 2004-09-22 | Heidelberg Pharma Holding GmbH | Phospholipid esters of clofarabine derivatives |
US20050187192A1 (en) * | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
US20050187191A1 (en) * | 2004-02-20 | 2005-08-25 | Kucera Louis S. | Methods and compositions for the treatment of respiratory syncytial virus |
MXPA06011219A (es) | 2004-03-29 | 2007-05-08 | Univ South Florida | Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados. |
EP1831235B1 (en) * | 2004-12-16 | 2013-02-20 | The Regents of The University of California | Lung-targeted drugs |
US20070003608A1 (en) * | 2005-04-08 | 2007-01-04 | Almond Merrick R | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
EP1868628B1 (en) * | 2005-04-08 | 2014-06-11 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
EP2012799B1 (en) * | 2006-05-03 | 2016-08-24 | Chimerix, Inc. | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates |
US20080249066A1 (en) * | 2007-03-23 | 2008-10-09 | Ardea Biosciences, Inc. | Antiviral compounds and compositions |
US9468607B2 (en) | 2007-10-09 | 2016-10-18 | Washington University | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
EP2209420A4 (en) | 2007-10-09 | 2014-01-22 | Univ St Louis | IMAGING PARTICLES |
JP5562255B2 (ja) * | 2008-01-25 | 2014-07-30 | キメリクス,インコーポレイテッド | ウイルス感染を治療する方法 |
EP2348864A4 (en) | 2008-10-08 | 2013-07-31 | Vascular Biogenics Ltd | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF |
ES2534044T3 (es) | 2008-11-06 | 2015-04-16 | Vascular Biogenics Ltd. | Compuestos de lípidos oxidados y usos de los mismos |
WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
US9764043B2 (en) | 2009-12-17 | 2017-09-19 | Washington University | Antithrombotic nanoparticle |
US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
AU2011239414A1 (en) | 2010-04-15 | 2012-11-08 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
US9192680B2 (en) | 2010-06-01 | 2015-11-24 | Aposense Ltd. | Pharmaceutical compounds |
US8530444B2 (en) * | 2010-06-01 | 2013-09-10 | Aposense Ltd. | Pharmaceutical compounds |
CN108619161A (zh) | 2013-03-15 | 2018-10-09 | 加利福尼亚大学董事会 | 无环核苷膦酸二酯 |
EA036391B1 (ru) | 2014-09-15 | 2020-11-05 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Нуклеотидные аналоги |
US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
ES2855299T3 (es) | 2014-11-26 | 2021-09-23 | Vascular Biogenics Ltd | Lípidos oxidados y tratamiento o prevención de la fibrosis |
EP3350191B9 (en) | 2015-09-15 | 2021-12-22 | The Regents of the University of California | Nucleotide analogs |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE279249C (US07026469-20060411-C00007.png) | ||||
US2108765A (en) | 1938-02-15 | Preserving and disinfecting media | ||
US2087132A (en) | 1933-04-13 | 1937-07-13 | Alba Pharmaceutical Company In | Quaternary ammonium compounds |
US2086585A (en) | 1933-04-13 | 1937-07-13 | Alba Pharmaceutical Company In | Quaternary ammonium compounds |
US2209383A (en) | 1938-03-05 | 1940-07-30 | Rohm & Haas | Process of waterproofing fabrics |
US2445393A (en) | 1944-03-08 | 1948-07-20 | Rhone Poulenc Sa | New amino-derivatives of dioxa-cyclopentane |
US2439969A (en) | 1944-04-17 | 1948-04-20 | Rhone Poulenc Sa | Amino-dioxacyclopentanes |
US2513747A (en) | 1945-10-04 | 1950-07-04 | Ciba Ltd | Cyclic amino-acetals |
US2606909A (en) | 1947-08-01 | 1952-08-12 | Univ Michigan | Basic dioxolanes |
US2689790A (en) | 1951-09-26 | 1954-09-21 | Monsanto Chemicals | Nitrogenous compound herbicides |
NL189533C (nl) | 1953-07-29 | Ates Componenti Elettron | Werkwijze voor het aanbrengen van een kunststofhouder met warmte-afvoer rond een geintegreerde schakeling, alsmede combinatie van een matrijs en een warmte-afvoerelement voor gebruik bij deze werkwijze. | |
US3054678A (en) | 1958-04-16 | 1962-09-18 | Michener Harold David | Preservation process with quaternary ammonium compounds |
DE1619043B2 (de) | 1967-04-07 | 1977-11-03 | Hoechst Ag, 6000 Frankfurt | Mittel zum weichmachen von textilien und gleichzeitigem vermitteln einer guten saugfaehigkeit |
US4119714A (en) | 1970-02-27 | 1978-10-10 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. | Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens |
DE2033359C3 (de) | 1970-07-06 | 1980-02-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Acylpropandiol-(l,3)-phosphorsäuremono-cholinester und Verfahren zu deren Herstellung |
JPS49100224A (US07026469-20060411-C00007.png) | 1973-01-29 | 1974-09-21 | ||
US4093714A (en) | 1974-03-15 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 9β-D-Arabinofuranosylpurine nucleotides and method of use |
US4159988A (en) | 1974-08-06 | 1979-07-03 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Synthetic phospholipids, a process for their manufacture and their use |
FR2356425A1 (fr) | 1976-07-01 | 1978-01-27 | Roussel Uclaf | Application a titre de medicaments de derives organiques de la montmorillonite |
US4291024A (en) | 1978-04-10 | 1981-09-22 | Turcotte Joseph G | Cytotoxic liponucleotide analogs |
DE2820893C2 (de) | 1978-05-12 | 1986-02-20 | A. Nattermann & Cie GmbH, 5000 Köln | Strukturanaloga von natürlichen Phospholipiden und Verfahren zur Herstellung dieser Verbindungen |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4329302A (en) | 1980-06-27 | 1982-05-11 | Board Of Regents, The University Of Texas System | Synthetic phosphoglycerides possessing platelet activating properties |
EP0050327B1 (de) | 1980-10-21 | 1984-06-20 | Roche Diagnostics GmbH | Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
JPS5772914A (en) | 1980-10-22 | 1982-05-07 | Takeda Chem Ind Ltd | Antitumor agent |
US4471113A (en) | 1982-02-03 | 1984-09-11 | The United States Of America As Represented By The Department Of Energy | Prodrugs based on phospholipid-nucleoside conjugates |
EP0094586A3 (en) | 1982-05-13 | 1984-06-06 | Ono Pharmaceutical Co., Ltd. | Glycerol derivatives, process for preparing same and pharmaceutical composition containing same |
US4661509A (en) | 1982-09-28 | 1987-04-28 | Gordon Arnold Z | Methods for treating leukopenia |
JPS5988447A (ja) | 1982-11-11 | 1984-05-22 | Ono Pharmaceut Co Ltd | グリセリン誘導体、その製造方法及びその誘導体を含有する薬剤 |
FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
JPS60100544A (ja) | 1983-11-08 | 1985-06-04 | Ono Pharmaceut Co Ltd | 新規なグリセリン誘導体,その製造方法及びその誘導体を含有する薬剤 |
JPS60104066A (ja) | 1983-11-10 | 1985-06-08 | Ono Pharmaceut Co Ltd | グリセリン誘導体 |
JPS60105650A (ja) | 1983-11-14 | 1985-06-11 | Ono Pharmaceut Co Ltd | グリセリン誘導体、その製造方法及びその誘導体を含有する薬剤 |
US4540521A (en) | 1984-01-16 | 1985-09-10 | National Distillers And Chemical Corporation | Liquid quaternary ammonium antistatic compositions |
US4622392A (en) | 1984-06-21 | 1986-11-11 | Health Research Inc. (Roswell Park Division) | Thiophospholipid conjugates of antitumor agents |
US4826823A (en) | 1985-02-05 | 1989-05-02 | Warner-Lambert Company | Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4724232A (en) | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
GB2175588B (en) * | 1985-04-15 | 1988-08-10 | Toyo Jozo Kk | Nucleoside-phospholipid conjugates |
JPS61238793A (ja) | 1985-04-17 | 1986-10-24 | Toyo Jozo Co Ltd | 新規リン脂質誘導体 |
US4619917A (en) | 1985-07-18 | 1986-10-28 | Sandoz Pharm. Corp. | Substituted 2-furanyl- or 5-oxo-2-furanyl methoxy phosphoryl alkyl cyclimmonium salts |
IE59778B1 (en) | 1985-12-04 | 1994-04-06 | Max Planck Gesellschaft | Medicament with anti-tumour action containing hexadecylphosphocholine |
US4841039A (en) | 1986-05-01 | 1989-06-20 | Emory University | 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents |
DE3619748A1 (de) | 1986-06-12 | 1987-12-17 | Merz & Co Gmbh & Co | Antimikrobielle mittel |
US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
DE3778626D1 (de) | 1986-09-27 | 1992-06-04 | Toyo Jozo Kk | Nukleosid-phospholipid-konjugat. |
US4880782A (en) | 1986-11-21 | 1989-11-14 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. | Method of treating viral infections in humans and compositions therefor |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
JP2598643B2 (ja) | 1987-07-24 | 1997-04-09 | わかもと製薬株式会社 | 抗アレルギー剤 |
DE3726945A1 (de) | 1987-08-13 | 1989-02-23 | Dietl Hans | L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel |
US4894389A (en) | 1987-10-02 | 1990-01-16 | Merrell Dow Pharmaceuticals Inc. | Novel aminoalkyl-substituted heterocyclic sulfur compounds |
US4997761A (en) | 1987-10-06 | 1991-03-05 | Houston Biotechnology Incorporated | Phosphatidyl treatment of viral disease |
US4797497A (en) | 1988-02-25 | 1989-01-10 | Amoco Corporation | Trimellitic anhydride purification process |
EP0335396A1 (en) | 1988-04-01 | 1989-10-04 | MAGIS FARMACEUTICI S.p.A. | Glycero-phosphoric and -diphosphoric acids derivatives of L-carnitine or L-carnitine esters |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
EP0348859A1 (en) | 1988-07-01 | 1990-01-03 | MAGIS FARMACEUTICI S.p.A. | 1,2-di-O-acyl glycero(DI)phosphate of L-carnitine and its derivatives, a process for their preparation and pharmaceutical formulations which contain them |
US5817638A (en) * | 1988-07-07 | 1998-10-06 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
CA2001401A1 (en) | 1988-10-25 | 1990-04-25 | Claude Piantadosi | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions |
GB8827337D0 (en) | 1988-11-23 | 1988-12-29 | Medical Res Council | Nucleoside analogues |
DD279249A1 (de) | 1989-01-01 | 1990-05-30 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diphosphat-1,2-di-o-alkylglycerolen und deren salzen |
US5221696A (en) | 1989-03-29 | 1993-06-22 | Alcon Laboratories, Inc. | Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs |
FI902821A0 (fi) | 1989-06-12 | 1990-06-06 | Res Found Mental Hygiene | Foerminskning av infektionsspridning medelst blodbehandlingsapparatur. |
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
DE3929217A1 (de) | 1989-09-02 | 1991-03-07 | Boehringer Mannheim Gmbh | Verwendung von phospholipid-derivaten als antivirale arzneimittel und neue phospholipide |
DE3934820A1 (de) | 1989-10-19 | 1991-04-25 | Boehringer Mannheim Gmbh | Verwendung von lecithin-analoga als antivirale arzneimittel und neue derivate |
GB2239243B (en) | 1989-12-22 | 1993-05-12 | Scras | Glycerol derivatives |
MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
DE3942933A1 (de) | 1989-12-23 | 1991-06-27 | Boehringer Mannheim Gmbh | Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate |
US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
DE4010228A1 (de) | 1990-03-30 | 1991-10-02 | Werner E G Prof Dr Mueller | Verfahren zur herstellung eines mittels gegen virale infektionen, vorzugsweise gegen aids |
US5134394A (en) * | 1990-04-12 | 1992-07-28 | Beadle Leigh P | Light aircraft navigation apparatus |
WO1991018914A1 (en) | 1990-05-29 | 1991-12-12 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
DE69119074T2 (de) | 1990-06-15 | 1996-12-12 | Univ Wake Forest | Kovalente-ther lipidnukleosid-konjugate |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
TW207544B (US07026469-20060411-C00007.png) * | 1990-08-20 | 1993-06-11 | Boehringer Mannheim Gmbh | |
US5563257A (en) * | 1990-08-20 | 1996-10-08 | Boehringer Mannheim Gmbh | Phospholipid derivatives of nucleosides |
DE4026265A1 (de) | 1990-08-20 | 1992-02-27 | Boehringer Mannheim Gmbh | Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel |
WO1992006192A1 (en) | 1990-10-09 | 1992-04-16 | Vestar, Inc. | Inhibition of viral replication |
JPH07500573A (ja) | 1991-07-12 | 1995-01-19 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | 抗ウィルス性リポヌクレオシド:b型肝炎の治療 |
MX9206219A (es) | 1991-10-28 | 1994-01-31 | Mona Industries Inc | Composiciones antimicrobianas de fosfolipidos |
DE4204032A1 (de) | 1992-02-12 | 1993-08-19 | Boehringer Mannheim Gmbh | Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel |
DE4204031A1 (de) | 1992-02-12 | 1993-08-19 | Boehringer Mannheim Gmbh | Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel |
GB9204015D0 (en) | 1992-02-25 | 1992-04-08 | Wellcome Found | Therapeutic nucleosides |
US6602861B1 (en) | 1992-04-16 | 2003-08-05 | Research Corporation Technologies, Inc. | Acylated phospholipid drugs |
US5512671A (en) | 1993-02-16 | 1996-04-30 | Wake Forest University | Ether lipid-nucleoside covalent conjugates |
AU6247594A (en) | 1993-02-24 | 1994-09-14 | Jui H. Wang | Compositions and methods of application of reactive antiviral polymers |
IL105244A (en) | 1993-03-31 | 2003-07-31 | Dpharm Ltd | Prodrugs with enhanced penetration into cells |
US6413949B1 (en) | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
DE69431596D1 (de) | 1993-06-10 | 2002-11-28 | Wake Forest University Winston | (phospho)lipide zum bekämpfen einer hepatitis b-infektion |
CA2126601A1 (en) | 1993-06-29 | 1994-12-30 | Mitsubishi Chemical Corporation | Phosphonate-nucleotide ester derivatives |
DE4321978A1 (de) | 1993-07-01 | 1995-01-12 | Boehringer Mannheim Gmbh | Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel |
EP0773029A4 (en) | 1993-07-19 | 1997-09-03 | Tokyo Tanabe Co | HEPATITIS C VIRUS PROLIFERATION INHIBITOR |
DE4402492A1 (de) | 1994-01-28 | 1995-08-03 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von unsymmetrischen Phosphorsäurediestern |
DE4418690A1 (de) | 1994-05-28 | 1996-01-11 | Boehringer Mannheim Gmbh | Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel |
AU3216695A (en) * | 1994-08-29 | 1996-03-22 | University Of North Carolina At Chapel Hill, The | Lipid analogs for treating viral infections |
JP3786447B2 (ja) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | C型肝炎の予防・治療剤 |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5891874A (en) | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
JP3927630B2 (ja) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウイルス感染症の予防・治療剤 |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
JP4080541B2 (ja) | 1996-10-18 | 2008-04-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
US6243759B1 (en) * | 1998-05-08 | 2001-06-05 | International Business Machines Corporation | Method and system for configuring dynamic interfaces |
IL131887A0 (en) * | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
US6670341B1 (en) * | 1999-10-28 | 2003-12-30 | Wake Forest University Health Sciences | Compositions and methods for double-targeting virus infections and targeting cancer cells |
JP4213841B2 (ja) | 2000-03-23 | 2009-01-21 | 大成建設株式会社 | 仮支承の施工方法 |
-
2001
- 2001-04-27 US US09/844,201 patent/US7026469B2/en not_active Expired - Lifetime
-
2002
- 2002-04-26 CA CA2445565A patent/CA2445565C/en not_active Expired - Fee Related
- 2002-04-26 WO PCT/US2002/013338 patent/WO2002087465A2/en active Application Filing
- 2002-04-26 EP EP02721822A patent/EP1389970A4/en not_active Withdrawn
- 2002-04-26 AU AU2002252731A patent/AU2002252731A1/en not_active Abandoned
- 2002-04-26 JP JP2002584819A patent/JP4782365B2/ja not_active Expired - Fee Related
-
2006
- 2006-04-06 US US11/398,529 patent/US7638528B2/en not_active Expired - Fee Related
-
2009
- 2009-12-02 US US12/629,387 patent/US8138200B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20100184718A1 (en) | 2010-07-22 |
WO2002087465A3 (en) | 2003-12-11 |
US20060264397A1 (en) | 2006-11-23 |
US7026469B2 (en) | 2006-04-11 |
US7638528B2 (en) | 2009-12-29 |
US8138200B2 (en) | 2012-03-20 |
US20020082242A1 (en) | 2002-06-27 |
CA2445565C (en) | 2013-07-09 |
EP1389970A2 (en) | 2004-02-25 |
CA2445565A1 (en) | 2002-11-07 |
EP1389970A4 (en) | 2005-07-06 |
JP2005505499A (ja) | 2005-02-24 |
WO2002087465A2 (en) | 2002-11-07 |
JP4782365B2 (ja) | 2011-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002252731A1 (en) | Compositions and methods of double-targeting virus infections and cancer cells | |
AU2002357119A1 (en) | Mitocidal compositions and methods | |
AU2002320058A1 (en) | Magnetic-nanoparticle conjugates and methods of use | |
AU2002363236A1 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
AU2002324914A1 (en) | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | |
AU2002345970A1 (en) | Stabilized compositions and processes of their preparation | |
AU2002327055A1 (en) | Topical compositions and methods of application | |
HK1048820A1 (zh) | 用於雙導向病毒感染和導向癌細胞的組合物和方法 | |
AU2003215027A1 (en) | Cyclodextrin compositions and methods of treating viral infections | |
AU2002364708A1 (en) | Novel compositions and methods for cancer | |
AU2002350079A1 (en) | Gel composition and methods of use | |
AU2002357748A1 (en) | Osteopontin-related compositions and methods | |
AU2002346882A1 (en) | Methods for the treatment of osteoarthritis and compositions thereof | |
AU2002337943A1 (en) | Novel compositions and methods for cancer | |
AU2002252387A1 (en) | Novel anti-inflammatory compositions and methods of use | |
AU2756301A (en) | Compositions comprising genome segments and methods of using the same | |
AU2002366809A1 (en) | Syn3 compositions and methods | |
AU2002337713A1 (en) | Pharmaceutical compositions and methods for treating cancer | |
AU4839100A (en) | Methods of using and compositions comprising n-desmethylzolpidem | |
AU2002332613A1 (en) | Compositions and therapeutic methods for viral infection | |
AU2002259005A1 (en) | Compositions and methods for inducing cancer cell death | |
AU2002242086A1 (en) | Chemomagnetic retrieval of cmv and cmv infected cells | |
AU2002327531A1 (en) | Therapeutic compositions and methods for treating viral infection | |
AU2002359869A1 (en) | Pak5-related compositions and methods | |
WO2003020115A9 (en) | Methods and compositions for the detection of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |